{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:40:36Z","timestamp":1793745636016,"version":"4.6.1"},"reference-count":85,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"12","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,4,20]]},"abstract":"\n \n \n This guideline has been updated.<\/jats:bold>\n <\/jats:p>\n \n This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the\n online dynamic version<\/jats:ext-link>\n for the latest updates.\n <\/jats:p>\n <\/jats:boxed-text>\n <\/jats:p>\n \n ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the<\/jats:italic>\n \n ASCO Guidelines Methodology Manual<\/jats:italic>\n <\/jats:ext-link>\n . ASCO Guidelines follow the<\/jats:italic>\n \n ASCO Conflict of Interest Policy for Clinical Practice Guidelines<\/jats:italic>\n <\/jats:ext-link>\n .\n <\/jats:p>\n \n \n Clinical Practice Guidelines and other guidance (\u201cGuidance\u201d) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in\n Appendix 1<\/jats:xref>\n and\n Appendix 2<\/jats:xref>\n (online only) for more\n <\/jats:italic>\n .\n <\/jats:p>\n \n PURPOSE<\/jats:title>\n To provide updated recommendations for immunotherapy and targeted therapy for patients with advanced gastroesophageal cancer.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n Twelve newly published or updated phase III randomized controlled trials met the inclusion criteria for the systematic review.<\/jats:p>\n <\/jats:sec>\n \n RECOMMENDATIONS<\/jats:title>\n The target population for these recommendations is patients with unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. Results from testing for actionable biomarkers should be available as soon as possible to inform treatment decision making. Immunotherapy with doublet chemotherapy is recommended for patients with proficient mismatch repair (pMMR)\/microsatellite stable (MSS) human epidermal growth factor receptor 2 (HER2)\u2013negative gastroesophageal adenocarcinoma or squamous cell carcinoma and PD-L1 expression \u22651; patients with higher PD-L1 expression are more likely to benefit from immunotherapy. Zolbetuximab is recommended for patients with gastroesophageal adenocarcinoma, PD-L1 <1, and positive CLDN18.2 expression. Patients with dual PD-L1 and CLDN18.2 positivity should engage in shared decision making, considering the factors outlined in the guideline. Doublet chemotherapy alone is recommended for patients who are not positive for actionable biomarkers or are not considered candidates for targeted therapy or immunotherapy. For patients with pMMR\/MSS HER2-positive gastric\/gastroesophageal junction (GEJ) adenocarcinoma, trastuzumab and doublet chemotherapy is recommended; for patients with PD-L1 expression \u22651, the addition of pembrolizumab is recommended. Immunotherapy alone or with doublet chemotherapy is recommended for patients with mismatch repair deficient\/microsatellite instability\u2013high gastroesophageal cancer. Second-line therapy options include ramucirumab with paclitaxel, trastuzumab deruxtecan for HER2-positive gastric\/GEJ adenocarcinoma, and immunotherapy for PD-L1 \u22651 esophageal squamous cell carcinoma after first-line combination chemotherapy without immunotherapy.<\/jats:p>\n \n Additional information is available at\n www.asco.org\/gastrointestinal-cancer-guidelines<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1200\/jco-25-02958","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T21:00:15Z","timestamp":1772139615000},"page":"1145-1165","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":12,"title":["Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update"],"prefix":"10.1200","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6913-9655","authenticated-orcid":false,"given":"Manish A.","family":"Shah","sequence":"first","affiliation":[{"name":"Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4370-7757","authenticated-orcid":false,"given":"Erin B.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1362-4387","authenticated-orcid":false,"given":"Dana","family":"Deighton","sequence":"additional","affiliation":[{"name":"Melanoma Research Alliance, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4357-9035","authenticated-orcid":false,"given":"Minaxi","family":"Jhawer","sequence":"additional","affiliation":[{"name":"Englewood Health, Englewood, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3574-4141","authenticated-orcid":false,"given":"Kunal C.","family":"Kadakia","sequence":"additional","affiliation":[{"name":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2153-3896","authenticated-orcid":false,"given":"Sarbajit","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Miami Cancer Institute, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4048-2692","authenticated-orcid":false,"given":"Christopher","family":"Nevala-Plagemann","sequence":"additional","affiliation":[{"name":"University of Utah Huntsman Cancer Center, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-9401","authenticated-orcid":false,"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan J.","family":"Schneider","sequence":"additional","affiliation":[{"name":"University of Michigan Health, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7810-5887","authenticated-orcid":false,"given":"Thomas","family":"Semrad","sequence":"additional","affiliation":[{"name":"Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":false,"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[{"name":"National Cancer Center East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Tenner","sequence":"additional","affiliation":[{"name":"University of Nebraska, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3449-1680","authenticated-orcid":false,"given":"Nataliya V.","family":"Uboha","sequence":"additional","affiliation":[{"name":"University of Wisconsin School of Medicine, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melani","family":"Vincelli","sequence":"additional","affiliation":[{"name":"Debbie's Dream Foundation, Plantation, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davit","family":"Zohrabyan","sequence":"additional","affiliation":[{"name":"Yerevan State Medical University, Yerevan, Armenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Rajdev","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_9_3_2","first-page":"13","article-title":"Overview of gastroesophageal junction cancers","volume":"3","author":"Oo AM","year":"2019","unstructured":"Oo AM, Ahmed S: Overview of gastroesophageal junction cancers. Mini-invasive Surg 3:13, 2019","journal-title":"Mini-invasive Surg"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01926"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31288-5"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/10732748221099227"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3237"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature20805"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/852748"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-00664-y"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01601"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101233"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijtm4040045"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02767"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31120572"},{"key":"e_1_3_9_18_2","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024)","author":"Higgins JPT","year":"2024","unstructured":"Higgins JPT, Thomas J, Chandler J, et al: (eds): Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Chichester, United Kingdom, Wiley, 2024"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876"},{"key":"e_1_3_9_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6"},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00108-0"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00620-7"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7235"},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.250"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01535-0"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_3_9_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503119"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61719-5"},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70420-6"},{"key":"e_1_3_9_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30739-3"},{"key":"e_1_3_9_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01888"},{"key":"e_1_3_9_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30626-6"},{"key":"e_1_3_9_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01173-w"},{"key":"e_1_3_9_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413"},{"key":"e_1_3_9_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00170"},{"key":"e_1_3_9_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare12151496"},{"key":"e_1_3_9_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103663"},{"key":"e_1_3_9_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102623"},{"key":"e_1_3_9_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100189"},{"key":"e_1_3_9_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02033-0"},{"key":"e_1_3_9_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03450-4"},{"key":"e_1_3_9_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy264"},{"key":"e_1_3_9_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.02.007"},{"key":"e_1_3_9_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836"},{"key":"e_1_3_9_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.28463"},{"key":"e_1_3_9_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068714"},{"key":"e_1_3_9_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918"},{"key":"e_1_3_9_50_2","unstructured":"Hertz DL Venook AP: Reducing fluorouracil doses in patients with partial dihydropyrimidine dehydrogenase deficiency is a treatment safety strategy not a panacea of precision dosing. JCO Precis Oncol 10.1200\/PO-25-00440"},{"key":"e_1_3_9_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-025-01660-4"},{"key":"e_1_3_9_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4"},{"key":"e_1_3_9_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103962"},{"key":"e_1_3_9_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01862"},{"key":"e_1_3_9_55_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09536-x"},{"key":"e_1_3_9_56_2","volume-title":"Presented at the 2024 ASCO Annual Meeting","author":"Shitara K","year":"2024","unstructured":"Shitara K, Van Cutsem E, Lordick F, et al: Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbe tuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER22, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma. Presented at the 2024 ASCO Annual Meeting. 2024"},{"key":"e_1_3_9_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"e_1_3_9_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100131"},{"key":"e_1_3_9_59_2","article-title":"Ending the controversy around pretreatment dihydropyrimidine dehydrogenase (DPD\/DPYD) testing heightens the controversy over appropriate fluoropyrimidine dosing","author":"Hertz DL","unstructured":"Hertz DL, Venook AP: Ending the controversy around pretreatment dihydropyrimidine dehydrogenase (DPD\/DPYD) testing heightens the controversy over appropriate fluoropyrimidine dosing. J Clin Oncol 10.1200\/JCO-25-02629 [epub ahead of print on January 16, 2026]","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_60_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105"},{"key":"e_1_3_9_61_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11004-z"},{"key":"e_1_3_9_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02629"},{"key":"e_1_3_9_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2093"},{"key":"e_1_3_9_64_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00480"},{"key":"e_1_3_9_65_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-023-01318-8"},{"key":"e_1_3_9_66_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2238896"},{"key":"e_1_3_9_67_2","unstructured":"Klempner SJ Cowden ES Cytryn SL et al: PD-L1 immunohistochemistry in gastric cancer: Comparison of combined positive score and tumor area positivity across 28-8 22C3 and SP263 assays. JCO Precis Oncol 10.1200\/PO.24.00230"},{"key":"e_1_3_9_68_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2085"},{"key":"e_1_3_9_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-022-00617-y"},{"key":"e_1_3_9_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2024.04.011"},{"key":"e_1_3_9_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00130-5"},{"key":"e_1_3_9_72_2","volume-title":"ESMO Congress 2025","author":"Rha SY","year":"2025","unstructured":"Rha SY: LBA10 - First-Line bemarituzumab improves short-term survival in gastric or gastroesophageal junction cancer overexpressing FGFR2b. ESMO Congress 2025. 2025"},{"key":"e_1_3_9_73_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.2311"},{"key":"e_1_3_9_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-9684(15)30409-0"},{"key":"e_1_3_9_75_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00174"},{"key":"e_1_3_9_76_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6706"},{"key":"e_1_3_9_77_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2518"},{"key":"e_1_3_9_78_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9123"},{"key":"e_1_3_9_79_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2011.000316"},{"key":"e_1_3_9_80_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.1183"},{"key":"e_1_3_9_81_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31050191"},{"key":"e_1_3_9_82_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.34020"},{"key":"e_1_3_9_83_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-024-01413-8"},{"key":"e_1_3_9_84_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00542"},{"key":"e_1_3_9_85_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00933"},{"key":"e_1_3_9_86_2","first-page":"2133","volume-title":"GRADE handbook for grading quality of evidence and strength of recommendations","author":"Sch\u00fcnemann H","year":"2013","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, et al (eds): GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group. pp, 2133-2141, 2013. guidelinedevelopment.org\/handbook"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-02958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:02:49Z","timestamp":1786114969000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-02958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":85,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,4,20]]}},"alternative-id":["10.1200\/JCO-25-02958"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-02958","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"2025-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}